Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | The impact of age on the prognosis of patients with ALL

Sabina Chiaretti, MD, PhD, Sapienza University of Rome, Rome, Italy, discusses factors affecting the prognosis of patients with acute lymphoblastic leukemia (ALL), emphasizing the important role that age plays in this disease. Dr Chiaretti suggests that the addition of immunotherapy, using either blinatumomab or inotuzumab ozogamicin, to the frontline treatment of elderly or higher-risk patients may achieve better outcomes.This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Pfizer: Other: advisory board; Gilead: Other: advisory board; Abbvie: Other: advisory board; Incyte: Other: advisory board; Amgen: Other: advisory board.